BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation, the leader in ultrasound facilitated drug delivery, today announced the appointment of Robert W. Hubert to the position of President and Chief Executive Officer.
Mr. Hubert, brings to EKOS more than twenty years of marketing, sales, and general management experience in a broad range of medical device companies, from start-up to Fortune 10 organizations. Most recently, Mr. Hubert was Vice President and General Manager of the Heart Valve Division of Medtronic Corporation. Mr. Hubert’s career also included executive positions with Cynosure, Inc., Instrumentation Laboratory, and Quantum Medical Systems, Inc. involving medical laser technology, critical care diagnostic products and diagnostic ultrasound. Prior experience includes progressive imaging system sales and sales management positions with General Electric Corporation Medical Systems Division. He received his BS in Engineering from the State University of New York, Stony Brook.
“We are pleased to welcome Bob to EKOS at this important time in our Company’s history,” said Peter Rule, speaking on behalf of the board of directors. “His experience and leadership in both early stage and established companies will serve EKOS well as the company builds on its early success.”
“I am very excited to be joining the EKOS team,” said Robert Hubert. “The unique EKOS ultrasound assisted drug delivery technology has demonstrated significant advantages in the treatment of peripheral vascular disease and is showing very promising results in investigational treatment of ischemic stroke. There is great potential for expanding the application of this technology to benefit patients in these and other therapeutic areas.”
About EKOS Corporation
EKOS Corporation, a privately held company based in Bothell, Washington, is the world leader in providing ultrasound-accelerated drug delivery catheters for diagnosis and therapy. The company’s EKOS® EndoWave® Peripheral Infusion System and EKOS® Micro-Infusion Catheter are cleared for the delivery of therapeutic agents, including clot-dissolving thrombolytics, into the peripheral vasculature of patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT). The EKOS Micro-Infusion Catheter is also cleared for the administration of contrast media into the brain. A Phase II study using the Micro-Infusion Catheter and sponsored by the National Institutes of Health (NIH), has shown promising results in the treatment of ischemic thrombo-embolic stroke. For more information about EKOS, visit: www.ekoscorp.com.
Contact: EKOS Corporation Douglas Hansmann, Ph.D., Chief Operating Officer 425-415-3111 Mobile: 206-915-1511 dhansmann@ekoscorp.com
Source: EKOS Corporation
